Instagram Outage Disrupts Thousands of U.S. Users 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
CAMBRIDGE, Mass., Aug. 30, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will participate in the following conferences in September:
- Citi’s 12th Annual Biotech Conference (panel discussion) on Wednesday, September 6, 2017 at 1:00 p.m. ET in Boston;
- Morgan Stanley’s 15th Annual Global Healthcare Conference (fireside chat) on Monday, September 11, 2017 at 4:15 p.m. ET in New York City;
- Cantor Fitzgerald’s 3rd Annual Healthcare Conference (presentation) on Tuesday, September 26, 2017 at 3:25 p.m. ET in New York City; and,
- Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology (fireside chat) on Wednesday, September 27, 2017 at 8:30 a.m. ET in New York City.
Replays of the webcasts will be available in the investor section of the company’s website at http://www.epizyme.com for 60 days following the call and presentation.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy and in relapsed and front-line disease. Using the Company's proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.
Contacts: Cheya Pope, Epizyme, Inc. [email protected] 617-229-7561 Monique Allaire, THRUST IR [email protected] (617) 895-9511
